Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Haematology and transfusion indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Heparin-induced thrombocytopenia

Haematology and transfusion · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

HIT is a prothrombotic emergency, not a bleeding syndrome. A compatible platelet fall with new thrombosis, skin necrosis or acute systemic reaction after heparin requires immediate 4Ts assessment, cessation of unfractionated and low-molecular-weight heparin including flushes, blood products or coated devices where relevant, and therapeutic non-heparin anticoagulation if clinical probability is intermediate or high and bleeding risk permits. Do not wait for laboratory confirmation.

Overview

Estimate HIT probability from platelet timing and thrombosis, stop every heparin source, use rational PF4 testing, and begin safe non-heparin anticoagulation before limb- or life-threatening thrombosis.

Heparin binds PF4 released from platelet granules. In susceptible patients, multimolecular complexes become antigenic and IgG immune complexes cross-link platelet Fc receptors. Activated platelets release more PF4 and procoagulant microparticles, monocytes express tissue factor and thrombin generation accelerates. Platelets are consumed, but haemorrhage is unusual; deep-vein thrombosis, pulmonary embolism, limb artery occlusion, myocardial or cerebral events and catheter or circuit thrombosis dominate.

Clinical probability controls testing. The platelet percentage fall is calculated from the post-heparin peak, not just whether the result crossed the laboratory lower limit. Timing considers initial exposure and heparin during the previous 100 days. Thrombosis, skin necrosis and an anaphylactoid reaction after intravenous heparin add probability; sepsis, surgery, DIC, drugs and mechanical devices subtract it. A low 4Ts score avoids indiscriminate PF4 assays, whose high sensitivity but limited specificity can mislead.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Haematology and transfusionOriginal SBA

Immediate high-probability HIT care

Seven days after unfractionated heparin, a patient's platelet count falls by 60% and a new proximal DVT is confirmed. The 4Ts score is high. What is the appropriate immediate action?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Haematology and transfusion topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Society for Haematology HIT guideline4Ts probability, laboratory sequence, heparin cessation and alternative anticoagulation.
  • BNF argatroban monographUK dosing, APTT titration, hepatic adjustment and warfarin interaction.
  • NICE venous thromboembolism recommendationsVTE diagnosis, anticoagulant choice and safety context when heparin is unsuitable.
  • MHRA heparin safety informationUK pharmacovigilance and adverse-reaction reporting for heparin-associated thrombocytopenia.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Management interrupts antibody stimulation and thrombin generation. Remove heparin infusions, prophylaxis, line flushes, dialysis or extracorporeal exposure and heparin-containing products after pharmacy and device review. Start argatroban, danaparoid, fondaparinux or a direct oral anticoagulant according to stability, organ function, procedures, evidence and local guidance. Confirm diagnosis with immunoassay and functional testing. Warfarin begins only after platelet recovery with overlap where required; if already given during acute HIT, stop it and give vitamin K under specialist guidance.

Key points

  • Immune HIT is caused by IgG against platelet-factor-4–heparin complexes, activating platelets, monocytes and coagulation and creating a high risk of venous and arterial thrombosis.
  • The platelet count typically falls by more than 50% beginning five to ten days after heparin, and the nadir can remain above 150 × 10^9/L.
  • Rapid-onset HIT can occur within 24 hours when heparin exposure in the preceding weeks has left circulating antibodies; delayed presentations can occur after heparin stops.
  • Use the 4Ts score—thrombocytopenia, timing, thrombosis and other causes—before ordering PF4 testing; a well-calculated low score makes immune HIT unlikely.
  • For intermediate or high probability, stop every heparin source and begin a non-heparin anticoagulant while testing, adjusted for bleeding, renal and liver function and procedures.
  • A sensitive PF4 immunoassay detects many non-pathogenic antibodies, so optical strength and a functional platelet-activation assay refine positive results.
  • Do not use a positive PF4 test without a compatible clinical probability to label HIT; false diagnosis creates bleeding risk, costly alternatives and a lifelong inaccurate allergy record.
  • Warfarin should not be started during acute thrombocytopenic HIT because rapid protein C depletion can cause venous limb gangrene and skin necrosis.

Aetiology

01

PF4-heparin immunisation

Exposure to unfractionated or low-molecular-weight heparin creates PF4 complexes that induce pathogenic IgG in a small proportion of treated patients.

02

Exposure and host modifiers

Risk is higher with unfractionated heparin, major surgery and prolonged exposure, while recent heparin permits faster recurrence through persisting antibodies.

Pathophysiology

  1. 1
    Fc-receptor platelet activation

    IgG-PF4-heparin complexes cross-link platelet FcγIIa receptors, causing aggregation, microparticle release and further PF4 secretion in a self-amplifying loop.

  2. 2
    Explosive thrombin generation

    Activated platelets, monocytes and endothelium increase tissue factor and coagulation, producing thrombosis out of proportion to the degree of thrombocytopenia.

  3. 3
    Platelet consumption

    Activated platelets are incorporated into thrombi and cleared, causing the characteristic relative count fall while severe spontaneous bleeding remains uncommon.

Clinical features and red flags

Relative platelet fall

A decline exceeding 50% from the post-heparin peak is important even if the absolute count remains within the reference range.

Typical timing

The fall begins five to ten days after first exposure or within a day when recent heparin antibodies persist.

New thrombosis

DVT, pulmonary embolism, limb ischaemia, catheter thrombosis or circuit clotting developing with the count change strongly raises probability.

Skin and bolus signs

Painful necrosis at injection sites or an acute systemic reaction after intravenous heparin can signal immune platelet activation.

Limb-threatening HITRed flag

Pain, pallor, pulselessness or neurological loss with a compatible count fall needs immediate vascular and haematology intervention.

Investigations

  1. 01
    Serial platelet countsFirst step
    Why
    Define percentage fall and timing from heparin exposure.
    Interpretation and limitations
    Use the highest relevant post-exposure count and search for a biphasic postoperative pattern; absolute nadir alone underestimates HIT.
  2. 02
    4Ts score
    Why
    Estimate pre-test probability before laboratory assays.
    Interpretation and limitations
    A carefully calculated low score makes immune HIT unlikely; intermediate or high scores trigger heparin cessation, testing and alternative anticoagulation.
  3. 03
    PF4-heparin immunoassay
    Why
    Detect antibodies against PF4-heparin complexes.
    Interpretation and limitations
    A negative sensitive assay argues against HIT, while positive strength must be combined with pre-test probability and functional confirmation.
  4. 04
    Functional platelet-activation assay
    Why
    Demonstrate pathogenic heparin-dependent antibody activity.
    Interpretation and limitations
    A positive assay strongly supports immune HIT; referral tests can take time and must not delay treatment of high-probability disease.
  5. 05
    Ultrasound or site-directed thrombosis imaging
    Why
    Find clinically suspected or silent thrombosis.

Differential diagnosis

01

Post-operative dilution

Surgery and fluids cause an immediate early platelet fall followed by recovery, whereas HIT classically begins later or shows a second decline.

02

Sepsis and DIC

Infection-related consumption produces organ dysfunction, prolonged coagulation and low fibrinogen, although critical illness and HIT can coexist.

03

Drug immune thrombocytopenia

Other medicines can cause profound isolated thrombocytopenia and bleeding without the heparin timing or dominant thrombotic phenotype.

04

Thrombotic microangiopathy

TTP and HUS produce schistocytes and microangiopathic haemolysis with neurological or renal injury rather than PF4-dependent thrombosis.

05

Mechanical consumption

ECMO, intra-aortic balloon pumps and dialysis circuits lower platelets through activation and shear and also expose patients to heparin, complicating probability assessment.

Management

01ProbabilityCalculate before testingFirst stepPlatelets fall or thrombosis appears during or after heparin exposure.+
  1. 1Calculate the exact percentage fall, exposure timing, thrombosis features and strength of competing causes using the 4Ts score.
  2. 2AlternativeFor a low score, seek the alternative cause and avoid indiscriminate PF4 testing unless new evidence changes probability.
  3. 3For intermediate or high probability, stop every heparin source, send immunoassay and functional confirmation and begin a suitable non-heparin anticoagulant.
02Acute treatmentRemove heparin and block thrombinClinical probability is intermediate or high and bleeding does not preclude anticoagulation.+
  1. 1Audit infusions, prophylaxis, flushes, dialysis, devices and blood products for hidden heparin and label it temporarily while confirmation proceeds.

Complications

01

Venous thromboembolism

Deep-vein thrombosis and pulmonary embolism are common and may be clinically silent, bilateral or catheter associated at the time thrombocytopenia is recognised.

02

Arterial limb ischaemia

Platelet-rich arterial thrombosis can threaten a limb, particularly when warfarin is started during acute HIT and natural anticoagulants fall rapidly.

03

Adrenal infarction

Bilateral adrenal-vein thrombosis can cause abdominal pain, hypotension, hyponatraemia and acute adrenal failure requiring immediate endocrine support.

04

Treatment-related bleeding

Alternative anticoagulants can accumulate in renal or liver dysfunction, and invasive procedures or critical illness increase bleeding during necessary therapeutic dosing.

Monitoring and follow-up

  • Repeat platelets daily during acute disease until recovery and calculate change from the true peak rather than a static lower-limit comparison.
  • Assess new limb, chest, abdominal, neurological, line and skin symptoms repeatedly because thrombosis can develop after heparin stops.
  • Monitor APTT for argatroban and product-specific renal, liver and bleeding parameters for the selected non-heparin anticoagulant.
  • Review PF4 immunoassay and functional results promptly and revise treatment and allergy documentation when the final probability changes.
  • During warfarin transition account for argatroban-related INR elevation and continue adequate non-heparin anticoagulation under the specialist protocol.
  • At discharge document whether HIT was suspected or confirmed, causative products, anticoagulant duration and future heparin advice precisely.

Special situations

A normal count can fall

Dropping from 380 to 170 represents a clinically important relative decline even though the final value remains within many reference ranges.

Testing follows probability

A sensitive immunoassay in a low-risk patient finds non-pathogenic antibodies and can create an enduring false diagnosis.

Stop means every source

Line flushes, dialysis circuits and some coated devices can continue antigen exposure after the visible infusion is discontinued.

Warfarin timing matters

Early protein C depletion during intense thrombin generation can precipitate venous limb gangrene despite an apparently therapeutic INR.

Common pitfalls

  1. 01

    Using the absolute count instead of percentage fall.

  2. 02

    Sending PF4 tests without a 4Ts score.

  3. 03

    Stopping prophylaxis but leaving heparin flushes.

  4. 04

    Waiting for functional confirmation before alternative anticoagulation.

  5. 05

    Starting warfarin before platelet recovery.

  6. 06

    Transfusing platelets routinely in a thrombotic syndrome.

Platelet transfusion is generally avoided unless serious bleeding or an essential procedure creates a compelling indication, because added platelets may fuel thrombosis.
  • After platelet recovery, anticoagulation duration depends on whether thrombosis occurred, and the confirmed reaction needs precise documentation for future surgery, dialysis and pregnancy.
    • Interpretation and limitations
    Image symptomatic limbs, lungs, lines or arteries urgently; local practice may screen lower limbs in confirmed isolated HIT.
  • 06
    Coagulation, renal and liver profile
    Why
    Assess alternatives and select non-heparin anticoagulant.
    Interpretation and limitations
    DIC changes mechanism; liver dysfunction prolongs argatroban, renal impairment constrains fondaparinux and many direct oral agents.
  • 07
    Blood film and haemolysis tests
    Why
    Identify TMA or other platelet mechanism.
    Interpretation and limitations
    Schistocytes with haemolysis redirect toward TTP, HUS, DIC or mechanical injury rather than isolated HIT.
    • 2
    Choose argatroban, danaparoid, fondaparinux or a direct oral anticoagulant with haematology from organ function, stability, procedures and local evidence.
  • 3Image symptomatic thrombosis and involve vascular or critical care for limb, pulmonary or organ compromise; do not transfuse platelets routinely.
    • 03TransitionConfirm diagnosis and plan future anticoagulationLaboratory results and platelet recovery clarify the episode.+
    1. 1Integrate immunoassay strength, functional result and clinical probability, removing an inaccurate HIT label when testing and course do not support it.
    2. 2Delay warfarin until platelet recovery and use appropriate overlap or transition; reverse any premature warfarin with vitamin K under specialist guidance.
    3. 3Set duration from isolated HIT versus HIT with thrombosis and issue precise patient-held documentation for future hospital, dialysis and surgery encounters.
    Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
    Provides rapidly adjustable direct thrombin inhibition during acute HIT, including severe renal impairment and procedure-prone illness.

    Argatroban

    Begin a specialist intravenous infusion at the licensed weight-based rate, using a lower starting dose in critical illness or liver dysfunction and titrating to the local APTT target.

    Hepatic clearance causes accumulation in liver disease; it raises INR and complicates warfarin transition, while bleeding and APTT confounders require expert titration.

    Provides non-heparin factor Xa inhibition with practical administration during clinically stable suspected or confirmed HIT.

    Fondaparinux

    For stable selected adults, use the licensed weight-based once-daily subcutaneous therapeutic dose off label for HIT under local guidance, adjusted or avoided in renal impairment.

    Renal accumulation, long half-life, low body weight, bleeding and urgent procedures limit use; it is not readily reversible and requires specialist selection.

    Offers oral non-heparin anticoagulation during platelet recovery or ongoing treatment in selected confirmed HIT.

    Direct oral anticoagulant

    Haematology may select an agent-specific acute VTE or transition regimen for stable patients, with dose based on renal function, liver function, interactions and thrombosis.

    Evidence and commissioning vary by scenario; avoid in unstable organ failure, pregnancy, major bleeding or when urgent procedures and absorption are uncertain.